Potential targets on Sanofi’s radar
09/09/20 -"In line with its strategy of expanding its focus on the immuno-oncology space and strengthening its internal R&D pipeline, Sanofi has spent €5.2bn on the acquisition of two small biotech firms ..."
Pages
66
Language
English
Published on
09/09/20
You may also be interested by these reports :
19/11/25
AstraZeneca has been beating the street’s estimates over the last few quarters, on the back of strong growth momentum for its oncology, rare disease, ...
18/11/25
Over past eighteen months, there has been a glaring performance divergence for family-owned Ipsen (BUY; France) vs. AV Small Pharmas. While the ...
17/11/25
Our 2025 estimates have been revised significantly, following a substantial guidance upgrade during Q3 results, driven by stronger-than-expected ...
14/11/25
The Q3 results surpassed expectations, driven by strong demand for depression and migraine medicines. Consequently, the management upgraded its ...